- $12.45m
- $3.86m
- $5.21m
Plus Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Plus Therapeutics Regains Compliance With Nasdaq Minimum Stockholders' Equity Requirement
Plus Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Fastenal, Target Hospitality , Encore Capital
Brief: Plus Therapeutics Granted U.S. FDA Orphan Drug Designation For Rhenium (186Re) Obisbemeda
Plus Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
Plus Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Plus Therapeutics Q3 Net Income USD -2.874 Million
Plus Therapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Plus Therapeutics And SpectronRx Announce Radiotherapeutic Manufacturing Partnership
Plus Therapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview
Plus Therapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Plus Therapeutics Files For Mixed Shelf Offering Of Up To $100 Million- SEC Filing
Brief: Plus Therapeutics Showcases New Interim Respect-Gbm Phase 2 Trial Data At The 2024 Congress Of Neurological Surgeons Annual Meeting
U.S. RESEARCH ROUNDUP-Adapthealth, Carnival, Phunware
Plus Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Plus Therapeutics Q2 Net Income USD -2.94 Million
Brief: Plus Therapeutics Presents Positive Clinical Trial Results At 2024 SNO/ASCO CNS Metastases Conference